It’s ladies’ night at The Reality Check! With Darren away, the rest of the crew is joined by Cristina Roach and Dina Tsirlin. First Dina discusses the role of race in biomedical research. Cristina then looks at whether reality TV is really real. Lastly Adam challenges the two couples to a skeptical version of the Newlywed Game.
Download direct: mp3 file
If you like the show, please leave us a review on itunes.
Race In Biomedical Research
Akinniyi, D. C., & Payne, P. W. (2011). BIDIL LESSONS: CARDIOLOGISTS VIEWS OF A RACE-BASED PERSONALIZED MEDICINE. Journal of the American College of Cardiology, 57(14s1), E1926-E1926.
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D’Agostino Jr, R., Ferdinand, K., … & Cohn, J. N. (2004). Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New England Journal of Medicine, 351(20), 2049-2057.
Doyle, J. M. (2006). What race and ethnicity measure in pharmacologic research. The Journal of Clinical Pharmacology, 46(4), 401-404.
Vaidyanathan G. Redefining clinical trials: the age of personalized medicine. Cell. 2012;148(6):1079-1080
Frueh, F. Personalized medicine: what is it? How will it affect health care? Paper presented at: 11th Annual FDA Science Forum; April 26, 2005; Washington, DC. . Accessed July 24, 2012
Bates, S. (2010). Progress towards personalized medicine. Drug discovery today, 15(3), 115-120.
Kahn, J. (2006). Genes, race, and population: avoiding a collision of categories. American Journal of Public Health, 96(11), 1965-1970.
Ross, C. J., Katzov-Eckert, H., Dubé, M. P., Brooks, B., Rassekh, S. R., Barhdadi, A., … & Hayden, M. R. (2009). Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature genetics, 41(12), 1345-1349.
Mesko, B., Zahuczky, G., & Nagy, L. (2012). The triad of success in personalised medicine: pharmacogenomics, biotechnology and regulatory issues from a Central European perspective. New Biotechnology, 29(6), 741-750.
Salmela, E., et al. 2011. Swedish population substructure revealed by genome-wide single nucleotide polymorphism data. PLoS One 6: 2: e16747
Greenbaum, D. (2012). Regulation and the fate of personalized medicine.The virtual mentor: VM, 14(8), 645.
Bolnick, D. A., Fullwiley, D., Duster, T., Cooper, R. S., Fujimura, J. H., Kahn, J., … & TallBear, K. (2007). The science and business of genetic ancestry testing. SCIENCE-NEW YORK THEN WASHINGTON-, 318(5849), 399.
Hinton, C. F., Grant, A. M., & Grosse, S. D. (2011). Ethical implications and practical considerations of ethnically targeted screening for genetic disorders: the case of hemoglobinopathy screening. Ethnicity & Health,16(4-5), 377-388.
Ali-Khan, S. E., Krakowski, T., Tahir, R., & Daar, A. S. (2011). The use of race, ethnicity and ancestry in human genetic research. The HUGO journal,5(1-4), 47-63.
Kaplan, J. B., & Bennett, T. (2003). Use of race and ethnicity in biomedical publication. JAMA: the journal of the American Medical Association,289(20), 2709-2716.
Hunt, L. M., & Megyesi, M. S. (2008). The ambiguous meanings of the racial/ethnic categories routinely used in human genetics research. Social science & medicine, 66(2), 349-361.
HCD Research, Inc. (2005). Physicians Believe Drugs Targeted for Ethnic and Racial Groups May Provide Therapeutic Advantages. Retrieved from http://www.businesswire.com/news/home/20050623005492/en/Physicians-Drugs-Targeted-Ethnic-Racial-Groups-Provide
Williams, M. J., & Eberhardt, J. L. (2008). Biological conceptions of race and the motivation to cross racial boundaries. Journal of Personality and Social Psychology, 94(6), 1033.
Lillquist, E., & Sullivan, C. A. (2006). Legal regulation of the use of race in medical research. The Journal of Law, Medicine & Ethics, 34(3), 535-551.
Brewer, R. M. (2006). Thinking critically about race and genetics. The Journal of Law, Medicine & Ethics, 34(3), 513-519.
Díaz-Perera, G., Bacallao, J., & Alemañy, E. (2012). Subpopulations with particular epidemiologic profiles and risks in Havana, Cuba: diabetes, hypertension, and tobacco-related illnesses. Revista Panamericana de Salud Pública, 32(1), 9-14.
Collier, R. (2012). A race-based detour to personalized medicine. Canadian Medical Association Journal, 184(7), E351-E353.
Chang T. (2012) Personalizing Medicine: Beyond Race. Virtual Mentor. American Medical Association Journal of Ethics. 13(8), 628-634.
Chan, S. L., Suo, C., Lee, S. C., Goh, B. C., Chia, K. S., & Teo, Y. Y. (2011). Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. The pharmacogenomics journal, 12(4), 312-318.
Krimsky, S. (2012). The short life of a race drug. The Lancet, 379(9811), 114-115
Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. The New England Journal of Medicine, 363(4), 301-4.
Hunt, L. M., & Kreiner, M. J. (2013). Pharmacogenetics in Primary Care: The Promise of Personalized Medicine and the Reality of Racial Profiling.Culture, Medicine, and Psychiatry, 1-10.
Malandrino, N., & Smith, R. J. (2011). Personalized medicine in diabetes. Clinical Chemistry, 57(2), 231-40.
McGregor, J. (2010). Racial, ethnic, and tribal classifications in biomedical research with biological and group harm. The American Journal of Bioethics, 10(9), 23-24.
Chan, I. S., & Ginsburg, G. S. (2011). Personalized medicine: progress and promise. Annual review of genomics and human genetics, 12, 217-244.
Tayo, B. O., Teil, M., Tong, L., Qin, H., Khitrov, G., Zhang, W., … & Bottinger, E. P. (2011). Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine. PloS one,6(5), e19166.
Burn, J. (2013). Should we sequence everyone’s genome? Yes. BMJ: British Medical Journal, 346.
McClellan KA, Avard D, Simard J, Knoppers BM. (2013). Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet. 21(2), 143–147
Cornetta K, Brown G. (2013).Balancing personalized medicine and personalized care. Acad Med. 88(3), 309–13.
McNearney TA, Hunnicutt SE, Fischbach M, et al. (2009). Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. J Rheumatol, 36(12), 2724-2732.
Lorusso, L. (2011). The justification of race in biological explanation.Journal of Medical Ethics, 37(9), 535-539.
Rajagopalan, R., & Fujimura, J. H. (2012). Will personalized medicine challenge or reify categories of race and ethnicity?. The virtual mentor: VM,14(8), 657.
Nevins, J. R., Huang, E. S., Dressman, H., Pittman, J., Huang, A. T., & West, M. (2003). Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Human molecular genetics, 12(suppl 2), R153-R157
Mascarenhas-Melo, F., Sereno, J., Teixeira-Lemos, E., Ribeiro, S., Rocha-Pereira, P., Cotterill, E., … & Reis, F. (2013). Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.Disease Markers, 35(2): 85–96
Cho, M. K. (2006). Racial and ethnic categories in biomedical research: there is no baby in the bathwater. The Journal of Law, Medicine & Ethics,34(3), 497-499.
Surbone, A. (2010). Cultural competence in oncology: where do we stand?.Annals of oncology, 21(1), 3-5.
Hamilton, J. A. (2008). Revitalizing difference in the HapMap: race and contemporary human genetic variation research. The Journal of Law, Medicine & Ethics, 36(3), 471-477